OMID HLDGS INC - OMID STOCK NEWS

OMID Holdings, Inc. (OTC Pink: OMID) released its Unaudited Financial & Disclosure Statements for the Year Ended December 31, 2021. Despite ongoing challenges since its reverse merger in early 2020, the company reports continuous growth. Chairman & CEO Adam Frank expressed optimism about 2022 as they prepare for an uplist. OMID specializes in health and wellness products, focusing on cannabis extracts and herbal ingredients. For more details, visit their official website.

OMID Holdings, Inc. (OTC Pink: OMID) reported strong financial results for Q4 and the year ended December 31, 2021. Q4 revenue reached $1,179,409, up 9% from Q3 and 141% from Q4 2020. Gross profit increased by 21% sequentially to $590,749, while net income before taxes also rose 11% to $469,034. For the year, OMID's total revenue surged 108% to $2,768,543, with a gross profit of $1,351,704, reflecting the company's profitable growth. CEO Adam Frank expressed pride in converting an accumulated deficit into retained earnings, signaling ambitious plans for uplisting to OTCQB.

OMID Holdings, Inc. (OTC Pink: OMID) has signed a 6-month marketing and consulting agreement with Toronto-based North Equities Corp for $60,000 and 150,000 restricted shares of OMID stock. This partnership aims to enhance the company's visibility across social media platforms. CEO Adam Frank affirms a commitment to transparency and operational improvements. As part of the agreement, a new YouTube channel has been launched to share vital updates about OMID. The company specializes in health and wellness products, particularly those containing cannabis extracts.

OMID Holdings, Inc. (OTC Pink: OMID) has retained M&K CPAS, PLLC to audit its financial statements for 2020, 2021, and 2022. The audits for 2020 and 2021 will commence immediately, targeting completion by Q2 2022. This move aims to prepare the company for SEC-reporting and an up-list to the OTCQB. CEO Adam Frank emphasized that this initiative, together with the company’s operational success, is expected to enhance stock liquidity and attract a broader range of investors.

OMID Holdings, Inc. (OTC Pink: OMID) released its unaudited financial statements for the third quarter, ending September 30, 2021. The company reported significant growth driven by its private label manufacturing operations. Chairman & CEO Adam Frank emphasized plans to enhance product types and manufacturing efficiency while maintaining quality and integrity. OMID specializes in developing health and wellness products, particularly those with cannabis extracts like CBD, at its FDA-registered facility in Phillipsburg, NJ.

OMID Holdings, Inc. (OTC Pink: OMID) has reported significant financial improvements for Q3 2021. Revenue increased by 378% from the previous quarter to $1,084,325, and gross profit rose 266% to $488,397. Year-to-date revenue reached $1,589,133, up 89% compared to 2020, with a net income of $526,287, a 184% increase. CEO Adam Frank expressed optimism about sustained growth as private label operations expand. OMID specializes in health and wellness products, focusing on cannabis extracts and herbal formulations.

OMID Holdings, Inc. (OTC Pink: OMID) has announced its initial investment in the legal psychedelic medicine sector by partnering with KetaMD, which provides at-home medical ketamine treatments. This investment, made in Q2, marks OMID's strategic entry into alternative medicines, aiming to enhance its identity as a life sciences company. CEO Adam Frank expressed optimism about the benefits of legal ketamine treatments aligning with their existing cannabis-related business, indicating future explorations in the health and wellness sector.

OMID Holdings, Inc. (OTC Pink: OMID) has released its unaudited financial statements for the quarter ending June 30, 2021. The company reports successful operational execution and anticipates record-breaking revenue for the third quarter. Management expects aggressive growth to continue, buoyed by the expansion of existing private label clients and the onboarding of new ones. OMID specializes in health and wellness products, particularly those containing cannabis extracts, from its FDA-registered facility in Phillipsburg, NJ.

OMID Holdings, Inc. (OTC Pink: OMID) announced a significant reduction of its outstanding common shares by 164 million, as requested by shareholders. This marks the second reduction this year, reflecting the board’s commitment to enhancing shareholder confidence and belief in the company’s long-term potential. OMID specializes in health and wellness products, particularly those containing cannabis extracts, manufactured in its FDA-registered facility in New Jersey.